Kolltan Pharmaceuticals Licenses Novel anti-KIT Antibodies and Related ... 4-traders (press release) Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced the Company has signed a license agreement with the University of Toronto for novel anti-KIT receptor tyrosine kinase antibodies identified in the laboratories of Dr. |
